Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 11 (3), 191-200

Diagnosing the Decline in Pharmaceutical R&D Efficiency


Diagnosing the Decline in Pharmaceutical R&D Efficiency

Jack W Scannell et al. Nat Rev Drug Discov.


The past 60 years have seen huge advances in many of the scientific, technological and managerial factors that should tend to raise the efficiency of commercial drug research and development (RD). Yet the number of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms. There have been many proposed solutions to the problem of declining RD efficiency. However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the number of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed. Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias. Our aim is to provoke a more systematic analysis of the causes of the decline in RD efficiency.

Similar articles

  • Discontinued Drugs in 2012: Cardiovascular Drugs
    HP Zhao et al. Expert Opin Investig Drugs 22 (11), 1437-51. PMID 23992034. - Review
    The continued high rate of cardiovascular morbidity and mortality has attracted wide concern and great attention of pharmaceutical industry. In order to reduce the attrit …
  • R&D Productivity Rides Again?
    D Lendrem et al. Pharm Stat 14 (1), 1-3. PMID 25336017. - Review
    A recent analysis of R&D productivity suggests that there are grounds for 'cautious optimism' that the industry 'turned the corner' in 2008 and is 'on the comeback tr …
  • Pharmaceutical R&D: The Road to Positive Returns
    E David et al. Nat Rev Drug Discov 8 (8), 609-10. PMID 19644471.
  • Improving R&D Productivity
    K Smietana et al. Nat Rev Drug Discov 14 (7), 455-6. PMID 26065405.
  • The Productivity Crisis in Pharmaceutical R&D
    F Pammolli et al. Nat Rev Drug Discov 10 (6), 428-38. PMID 21629293. - Review
    Advances in the understanding of the molecular basis of diseases have expanded the number of plausible therapeutic targets for the development of innovative agents in rec …
See all similar articles

Cited by 263 PubMed Central articles

See all "Cited by" articles


    1. Nat Rev Drug Discov. 2011 Jun;10(6):428-38 - PubMed
    1. Int J Health Care Finance Econ. 2005 Mar;5(1):47-73 - PubMed
    1. Nat Rev Drug Discov. 2009 Dec;8(12 ):959-68 - PubMed
    1. Mol Divers. 1997;2(4):217-22 - PubMed
    1. Nat Biotechnol. 1997 Apr;15(4):328-30 - PubMed

MeSH terms


LinkOut - more resources